Geron, a biopharmaceutical company developing cancer therapeutics, has appointed Graham Cooper as executive vice president (EVP), finance and business development and chief financial officer (CFO). Cooper will provide direction for all financial matters for Geron and be responsible for new business opportunities and investor relations for the company.
From 2006 until 2011, Cooper served as senior vice president (SVP), CFO and treasurer of Orexigen Therapeutics. He was instrumental in growing Orexigen from a venture-backed start-up into a sizeable public company, completing a large Phase 3 obesity programme and filing an non-disclosure agreement (NDA) with the Food and Drug Administration (FDA).
Previously, Cooper held the position of director, healthcare investment banking at Deutsche Bank Securities, where for over eight years he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field.
Cooper has earned a certified public accountant (CPA) and holds a BA in Economics from the University of California at Berkeley and an MBA from the Stanford Graduate School of Business.
The annual BNP Paribas Cash Management University kicked off on Thursday morning with treasury professionals congregating in Paris from across Europe.
APIs may be a solution to MT940 challenges, says Karen Fagan, treasury operation manager, for British television company, ITV.
Kicking off the first day of the Singapore Fintech Festival, issues with cryptocurrencies were addressed by MIT media labs director, Joi Ito, and panels of technology leaders discussed how they’re using data analytics.
Sibos 2017 day two highlights: Brexit and banking, and why ‘data is the new oil’ in financial services
How nation first politics can impact global financial organisations It’s clear that data and regulation are the two key topics that are ... read more